Jeff  Guo

Jeff Jianfei Guo

Professor

Kowalewski Hall

281

Pharmacy Guo Research - 0004

Professional Summary

Jeff J. Guo, PhD, is a Professor at College of Pharmacy and Dept of Public Health Sciences at College of Medicine.  He has been teaching multiple courses, e.g., Pharmacoepidemiology & Drug Safety, Clinical Trial Phase III & IV, Evidence-based Pharmacotherapy, and Pharmaceutical Economics & Policy.  He has mentored 10 PhD and numerous MS and PharmD students.  Prior to joining UC, he worked at the US Pharmacopeia, the Degge Group Ltd. and at the China Food & Drug Administration.  He is a Co-Editor for Value-in-Health Regional Issues, and sits on multiple editorial boards like Research in Social Administrative Pharmacy and American Health & Drug Benefits. He is a founder and the past Chair for ISPOR Asian Consortium.  He has extensive project experience on Medicaid drug utilization reviews and health policy research, the U.S. Pharmacopeia Drug Information, and the U.S. national medication error report system (MedMARx®).  He published numerous papers and textbook chapters, including JAMA, Lancet, Ann Intern Med, Pharmacoepidemiology Drug Safety, J Clin Psych, Pub Health Reports, Stroke,  Pharmacoeconomics, Value in Health and Ann Pharmacotherapy. His research areas include drug utilization review, drug price, market competition, rare disease and orphan drugs, drug-induced diseases, drug safety surveillance, cost-benefit analysis, as well as an evaluation of health outcomes for children and adolescences.
 

Research and Practice Interests

Pharmacoeconomics, health outcomes, pharmacoepidemiology, drug utilization review, drug safety and pharmacovigilance, pharmaceutical policy, clinical informatics, analysis of medical record and claims databases

Research Support

Investigators:PI: Guo. Bristol-Myers Squibb Company. Epidemiology and Health Utilization Study for Patients with Bipolar Disorder in Managed Care Population.

Investigators:PI: Guo Health Foundation of Greater Cincinnati Evaluation of health utilization and outcomes for Medicaid recipients enrolled in School-Based Health Centers (SBHC).

Investigators:PI: Cluxton; Co-PI: Guo. Ohio Medicaid Agency Medicaid retrospective drug utilization review and health service research program for Ohio.

Investigators:PI: Guo. URC Acute pancreatitis associated with different combination therapies between HIV-infected patients in Medicaid.

Investigators:Guo (PI) Health Foundation of Greater Cincinnati Health-related Quality of Life and Cost-Effectiveness Analysis for School-Based Health Centers for Children and Adolescents

Investigators:Guo (PI) Janssen Pharma Drug-Drug Interaction Associated with Antipsychotics in Patients with Schizophrenia and/or Bipolar Disorder

Investigators:Heaton (PI), Co-Investigators: Guo JJ, Kelton CML, Martin J, Cavanaugh T. 06-2008 -05-2009 Eli-Lilly Company "Economic cost and epidemiology for alcoholism and heavy alcohol drinkers" Active Type:Grant

Investigators:Heaton (PI), Co-Investigators: Cluxton RC, Guo JJ. 07-2008 -06-2009 Ohio Medicaid Agency “Retrospective drug utilization review for the Ohio State Medicaid program.” Active Type:Grant

Investigators:Guo, Jianfei 11-01-2003 -07-31-2006 Bristol-Myers Squibb Co. Epidemiology and Health Utilization Study for Medicaid Patients with Bipolar Disorder Role:PI $192,302.00 Closed Level:Industry

Grant: #2002-UC-28-01-A0-S0-E0 Investigators:Guo, Jianfei 02-15-2002 -12-31-2003 Health Foundation of Greater Cincinnati Evaluation of Health Outcomes & Costs Among Medicaid Recipients Enrolled in School-Based Health Centers Role:PI $153,067.00 Closed Level:Private Non-Profit

Grant: #SRS 004962 Investigators:Guo, Jianfei 01-01-2007 -08-31-2008 Health Foundation of Greater Cincinnati Impact of School-Based Health Centers on Health Utilization and Outcomes among Students in Greater Cincinnati Area Role:PI $28,000.00 Closed Level:Private Non-Profit

Grant: #PAL-OUT-009 Investigators:Guo, Jianfei; Keck, Paul 03-01-2007 -08-31-2010 Ortho-McNeil, Inc. Drug-Drug Interactions with Atypical Antipsychotic Medications in Patients with Schizophrenia and Bipolar Role:PI $160,560.00 Closed Level:Industry

Grant: #SRS 005700 Investigators:Boone, Jill; Buring, Shauna; Guo, Jianfei; Heaton, Pamela; Hein, Bradley; Tran, Giao 07-10-2008 -05-10-2009 Eli Lilly and Company Heavy Drinking and Alcohol Dependence Role:Collaborator $74,450.00 Closed Level:Industry

Grant: #SRS 006281 Investigators:Guo, Jianfei; Kelton, Christina; Wigle, Patricia 05-26-2009 -05-25-2014 Novartis Farmaceutica, SA Serious Asthma Exacerbation Role:PI $295,843.00 Active Level:Foreign Industry

Grant: #C4130555 Investigators:Guo, Jianfei; Pruemer, Jane 04-01-2011 -04-30-2014 Genentech, Inc. Treatment Patterns Among Patients with Gastric Cancer in China and USA Role:PI $55,881.00 Active Level:Industry

Grant: #MEDTAPPFY12 Investigators:Boone, Jill; Brewer, David; Cavanaugh, Teresa; Cluxton, Robert; Doherty, Michael; Draeger, Robert; Guo, Jianfei; Healy, Daniel; Heaton, Pamela; Hein, Bradley; Horner, Ronnie; Kelton, Christina; Kim, Karissa; Meganathan, Karthikeyan; Metzger, Anne; Wigle, Patricia 07-01-2011 -06-30-2013 Ohio Department of Jobs and Family Services Evaluation of Medicaid Prescription Drug Use Role:Collaborator $292,660.00 Closed Level:State of Ohio

Grant: #60034413 \ G1213-07-0343 Investigators:Guo, Jianfei 01-01-2012 -06-30-2012 Centers for Medicare & Medicaid Services MEDTAPP - Clinical Profile of Children with Severe Emotional Disorders Role:PI $7,624.00 Closed Level:Federal

Grant: #LEL Global Health Investigators:Guo, Jianfei; Wigle, Patricia 02-26-2013 -11-26-2013 Eli Lilly and Company Healthcare Utilization and Treatment Patterns for Patient with Acute Coronary Syndrome Role:PI $131,620.00 Active Level:Industry

Grant: #A-1213-07-0343-UC-PH Investigators:Boone, Jill; Brown, Bethanne; Cavanaugh, Teresa; Cluxton, Robert; Doherty, Michael; Epplen, Kelly; Guo, Jianfei; Heaton, Pamela; Hein, Bradley; Kelton, Christina; Kim, Karissa; Metzger, Anne; Wigle, Patricia 07-01-2012 -06-30-2013 Department of Health and Human Services Evaluation of Medicaid Prescription Drug Use Role:Collaborator $282,600.00 Active Level:Federal

Grant: #MEDTAPP - FY14 Investigators:Boone, Jill; Brewer, David; Brown, Bethanne; Cavanaugh, Teresa; Cluxton, Robert; Doherty, Michael; Epplen, Kelly; Guo, Jianfei; Heaton, Pamela; Hein, Bradley; Kelton, Christina; Metzger, Anne; Wigle, Patricia; Witzke, Robert 07-01-2013 -06-30-2014 Department of Health and Human Services MEDTAPP - FY14 Role:Collaborator $272,382.00 Active Level:Federal

Grant: #MEDTAPP FY15 Investigators:Boone, Jill; Brewer, David; Brown, Bethanne; Cavanaugh, Teresa; Cluxton, Robert; Doherty, Michael; Epplen, Kelly; Guo, Jianfei; Heaton, Pamela; Hein, Bradley; Kelton, Christina; Metzger, Anne; Wigle, Patricia 07-01-2014 -06-30-2015 Department of Health and Human Services MEDTAPP FY15 Role:Collaborator $244,593.75 Active Level:Federal

Grant: #ODHE sub MEDTAPP Investigators:Boone, Jill; Brewer, David; Brown, Bethanne; Cavanaugh, Teresa; Cluxton, Robert; Doherty, Michael; Epplen, Kelly; Guo, Jianfei; Heaton, Pamela; Hein, Bradley; Kelton, Christina; Luder, Heidi; Metzger, Anne; Wigle, Patricia 07-01-2015 -06-30-2016 Centers for Medicare & Medicaid Services MEDTAPP-FY16 Role:Collaborator $251,010.00 Active Level:Federal

Grant: #ODHE sub MEDTAPP G-1617-05-0132 Investigators:Boone, Jill; Brewer, David; Brown, Bethanne; Cavanaugh, Teresa; Cluxton, Robert; Epplen, Kelly; Guo, Jianfei; Heaton, Pamela; Hein, Bradley; Hincapie Echeverri, Ana Lucia; Kelton, Christina; Luder, Heidi; Metzger, Anne; Wigle, Patricia 07-01-2016 -06-30-2017 Centers for Medicare & Medicaid Services MEDTAPP - FY17 Role:Collaborator $253,217.00 Awarded Level:Federal

Publications

Peer Reviewed Publications

Guo JJ, Wigle R. P, Lammers K, Vu O. (2005. ) Comparison of Potentially Hepatotoxic Drugs in Major US Drug Compendia .J Res Social & Administrative Pharmacy, , 8 (3 ) ,460-479

Guo JJ, Jang R, Louder A, Cluxton RJ. (2005. ) Acute Pancreatitis Associated with Different Drug Therapies among HIV-infected Patients .Pharmacotherapy, , Vol 25 (8 ) ,1044-1054

Guo JJ, Kelton CML, Pasquale MK, Zimmerman J, Patel A, Heaton PC, Cluxton RJ. (2004. ) Price and Market-Share Competition of Anti-Ulcer Gastric Medications in the Ohio Medicaid Market .Int J Pharmaceutical Medicine, , Vol.18 (5 ) ,271-282.

Liu GG, Guo JJ*, Smith SR. (2004. ) HIV/AIDS Epidemic and Economic Costs to Business .Pharmacoeconomics, , Vol.22 (18 ) ,1181-1194

Guo JJ, Curkendall S, Jones J, Fife D, Goehring E, She DW. (2003. ) The impact of cisapride label change on codispending of contraindicated medications .J Pharmacoepidemiology Drug Safety, , (12 ) ,295-301.

Johnston JA, Cluxton, RJ, Heaton PC, Guo JJ, Moomaw CJ, Eckman MH. (2003. ) Predictors of Warfarin Use among Ohio Medicaid Patients with New-Onset Nonvalvular Atrial Fibrillation .Arch Intern Med , , (163 ) ,1705-1710

Jones JK, Fife D, Curkendall S, Guo JJ, et al. (2001. ) Coprescribing and codispensing of cisapride and contraindicated drugs .JAMA-Journal of American Medical Association, , 286 (13 ) ,1607-1609

Guo JJ, Diehl MC, Felkey BG, Gibson JT, and Barker KN. (1998. ) Comparison and analysis of the national drug code systems among drug information databases .Drug Information Journal, , 32 (3 ) ,769-775

Jing YH, Guo JJ*, Li X. (2006. ) Pregnancy registry research: FDA Guidance and Case Studies .Chinese Journal of Pharmacovigilance, , 3 (2 ) ,72-80

Guo JJ, Keck PE, Li H, Corey-Lisle PK, et al. (2006. ) Diabetes mellitus associated with antipsychotic use among patients with bipolar disorders: a population-based case-control study .J Clin Psych , , 67 (7 ) ,1055-1061

Chen Y, Guo JJ, Jiang DM, Zhang SY. (2006. ) Data mining methods for signals of drug adverse reactions [Part 1][Part 2] .Chinese Journal of Pharmacoepidemiology , , 15 (1 ) ,43-46

Neuss MN, Desch CE, McNiff KK, Eisenberg PD, Guo JJ, et al. (2005. ) A process for measuring the quality of cancer care: the quality oncology practice initiative (QOPI) .J Clin Oncology, , 23 (25 ) ,6233-9

Guo JJ, Gibson JT, Hancock GR, and Barker KN. (1995. ) Retrospective drug utilization review and the behavior of Medicaid prescribers: an empirical analysis .Clinical Therapeutics, , 17 (6 ) ,1174-87

Jing YH, Kelton CML, Guo JJ*, Chen Y, Li X, Wigle PR. (2006. ) Price and utilization of HMG Co-A reductase inhibitors (Statins) in the US Medicaid program .Drug Benefit Trends , , 18 (11 ) ,580 -592

Heaton PC, Guo JJ, Cluxton RC, Jang R, Horning R. (2006. ) Analysis of the effectiveness and cost benefit of leukotriene modifiers in adults with asthma in the Ohio Medicaid population .J Manag Care Pharm, , 12 (1 ) ,33 -42

Guo JJ, Keck PE, Li H, Corey-Lisle PK, Jiang DM, Jang R, L’Italien GJ. (2007. ) Diabetes associated with antipsychotic use among Medicaid patients with bipolar disorders: a nested case-control study .Pharmacotherapy , , 27 (1 ) ,27 -35

Kelton CML,Dusing ML, Ferrand Y, Rebelein RP, Guo JJ. (2007. ) Analysis of Pharmaceutical Products with Large Price Changes in Regional Hospital System .J Pharm Fin Econ Policy, , 16 (2 ) ,61 -86

Jing YH, Kelton CML, Li X, Guo JJ. (2007. ) Lethal drug probe in China – a case of Xinfu clindamycin .Pharmacoepidemiology Drug Safety, , (16) ,928 --932.

Chen Y, Patel NC, Guo JJ, Zhan S. (2007. ) Antidepressant prophylaxis for poststroke depression: a meta-analysis .International Clinical Psychopharmacology, , 22 (3 ) ,159 -166

Chen Y, Guo JJ, Healy D, Zhang S. (2007. ) Effect of integrated traditional Chinese medicine and Western medicine on SARS treatment: a meta-analysis study .Pharmacy Practice, , 5 (1) ) ,1 -9

Li X, Jing Y, Guo JJ. (2007. ) The reintroduction of natalizumab and its risk management plan .Chinese J Pharmacovigilance , , 4 (1) ) ,14 -17

Jing YH, Kelton CML, Guo JJ, Chen Y, Li X, Patel NC. (2007. ) Drug utilization, price, and market-share competition among antipsychotics in US Medicaid programs .Drug Benefit Trends, , 19 (1 ) ,27 -41

Jing Y, Li X, Guo JJ. (2006. ) Drug-induced hepatotoxicity and FDA white papers .Chinese Journal of Pharmacovigilance, , 3 (6 ) ,325 -328

Du W, Jing Y, Kelton CML, Guo JJ. (2007. ) Analysis and comparison of post-marketing surveillance between China and other countries. .Value in Health, Suppl. , , 11 (1 ) ,S130 --S136

Jing Y, Klein P, Kelton CML, Li X, Guo JJ. (2007. ) Drug price, utilization, and spending of antiretroviral medication in the U.S. Medicaid programs. .AIDS Research & Therapy , , 4 (22 ) ,1-8

Kelton CML, Ferrand Y, Heaton PC, Guo JJ. (2008. ) Impact of health policy on use of antidepressant drug in the US Medicaid program. J Mental Health Policy Economics. 11 (1 ) ,35- -49.

Wade TJ, Keller KN, Guo JJ, Huentelman T, Line K, Mansour ME (2008. ) Access and utilization patterns across the first three years of implementation of elementary and middle school school-based health centers . Public Health Reports, , 123 (6 ) ,739-750

Guo JJ, Wade TJ, Keller KN. (2008. ) Impact of School-Based Health Centers on Students with mental health problems .Public Health Reports, , 123: (5 ) ,768-80

Chen Y, Patel NC, Wulsin L, Guo JJ (02-2008. ) Risk of Cerebral Vascular Diseases associated with antidepressant use in a large managed care population: population-based case-control study .Annals Pharmacotherapy, , 42 (2: ) ,177 -184

Chen Y, Guo JJ, Li H, Patel NC (2009. ) Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter? .Pharmacoepidemiol Drug Saf , , 18 (3 ) ,196 --202.

Chen Y, Kelton CML, Jing YH, Li X, Guo JJ (2008. ) Trend analyses of utilization, price, and spending for antidepressant drugs in the US Medicaid program .J Res Social Administrative Pharmacy, , 4: ,244-257

Guo JJ, Keck PE, Li H, Jang R, Kelton CML (2008. ) Treatment costs and health utilization for patients with bipolar disorder in a large US managed care population .Value in Health, , 11 (3 ) ,416 -423

Chen Y, Guo JJ, Healy D, Patel NC (2008. ) Risk of Hepatotoxicity Associated with the Use of Telithromycin: Signal Detection Based upon the FDA’s Spontaneous Reporting System .Annals Pharmacotherapy, , 42 (12: ) ,1791 --6

Demland J, Jing Y, Kelton CML, Guo JJ, Li H, Wiggle PR (2009. ) Drug utilization pattern and off-label use of atypical antipsychotics in patients with bipolar disorder: 1998-2002 .Am Health Drug Benefit, , 2 (4 ) ,184 --191.

Chen Y, Guo JJ**, Steinbuck M, Lin XD, Buncher CR, Patel C. (2008. ) Comparisons of Data Mining Algorithms for Adverse Drug Reactions: An Empirical Study based on the Adverse Event Reporting System of the Food and Drug Administration .J Pharm Med , , 22 (6 ) ,359 --65

Guo JJ, Kelton CML. (2009. ) The role of epidemiology for drug development .Am Health Drug Benefit. , , 2 (1 supplement ) ,S49 --54

Roddy J, Partridge S, Rockey M, Pruemer J, Guo JJ, Desai S, Safa M. (2010. ) Thromboembolic Events in Patients with Colorectal Cancer Receiving the Combination of Bevacizumab-based Chemotherapy and Erythropoietin Stimulating agents. .Am J Clinical Oncology , , 33 (1 ) ,36 -42

Guo JJ, Jing Y, Nguyen K, Fan H, Li X, Kelton CM (2008. ) Principal components analysis of drug utilization and expenditure trends for major therapeutic classes in U.S. Medicaid programs. Journal of Medical Economics, , 11: (671- ) ,694

Wang JB, Guo JJ**, Yang L, Zhang YD, Sun ZQ, Zhang YJ (2010. ) Rare diseases and legislation in China. .The Lancet , , 375: ,708- -709

Chen Y, Guo JJ**, Steinbuck M, Buckley PF, Patel C. (2009. ) Risk of neuroleptic malignant syndrome associated with the use of antipsychotics in patients with bipolar disorder: a retrospective, population-based case-control study. .International J Psychiatry Med. , , 39 (4 ) ,439- -450

Yan WC, Zhang YJ, Guo JJ. (2010. ) Still some way to go in China: international tobacco control. [commentary] .British Medical Journal BMJ, , 341: ,c6659.

Bian B, Kelton CML, Guo JJ*, Wigle PR. (2010. ) Evaluating safety of long-acting beta agonists (LABAs) in patients with asthma. .Current Drug Safety., , 5 (3 ) ,245- -250

Guo JJ, Li S, Li X, Lee K, Hu S. (2010. ) Assessment of Use of Pharmacoeconomics and Outcomes Research in Asia: The ISPOR Asia Consortium Needs Survey Report. ISPOR Connection, , 16 (1 ) ,11 -13

Zhang YJ, Wang YO, Li L, Guo JJ, Wang JB (2011. ) China’s first rare-disease registry is under development. .The Lancet, , 378: ,769 --770

Vaidya S, Guo JJ*, Heaton PC, Steinbuch M. (2010. ) Comparison of post-marketing drug safety surveillance in some developing countries. .Drug Information Journal. , , 44 (3 ) ,519- -533

Guo JJ, Tsai K, Kelton CML, Bian B, Wigle PR (2011. ) Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma. .Ann Allergy Asthma Immuno, , 106 (3 ) ,214- -222

Zhang YJ, Liu WW, Wang JB, Guo JJ. (2011. ) Potentially inappropriate medication use among elderly population in the US population. .Age and Aging, , 40 (3 ) ,398- -401

Guo JJ, Pandey S, Doyle J, Bian B, Raisch D. (2010. ) A review of current risk-benefit assessments for drug safety. .Value in Health. , , 13 (5 ) ,657 -666

Bian BB, Guo JJ*, Kelton CML, Wigle PR (2010. ) Utilization and expenditure trends of ACE inhibitors and ARBs in the Medicaid program. .J Managed Care Pharmacy, , 16 (9 ) ,671- -679

Wade TJ, Guo JJ (2010. ) Cost-effectiveness analysis for the school-based health centers program. J Am Pub Health Assoc. , , 100 (5 ) ,1611 -1616

Chiu S, Guo JJ, Wigle PR, Lin A, Szeinbach S (2011. ) Drug utilization for anti-asthmatic medications in the US Medicaid program .Am Health Drug Benefit , , 4 (3 ) ,140- -149

Guo JJ, Wade TJ, Pan W, Keller KN. (2010. ) School-Based Health Centers: cost-benefit analysis and healthcare disparity. .J Am Pub Health Assoc. , , 100 (5 ) ,1617 -1623

Gorevski E, Bian B, Kelton CML, Boone JEM, Guo JJ. (2012. ) Evidence-based prediction of statin use with lipid-panel data from the National Health and Nutrition Examination Survey. .Value-in-Health., , 15: ,32- -38

Bian BB, Guo JJ*, Kelton CML, Wigle PR. (2010. ) Utilization and expenditure trends of ACE inhibitors and ARBs in the Medicaid program. .J Managed Care Pharmacy. , , 16 (9: ) ,671- -679

Guo J, Kelton CML, Guo JJ. (2012. ) Recent developments, utilization, and spending trends for Pompe disease therapies. .Am Health Drug Benefit , , 5 (3 ) ,182- -189

Yang BM, Lee K, Chaiyakunapruk N, Guo J. (2012. ) Widening Horizon of Pharmacoeconomics and Outcomes Research in the Asia-Pacific Region and the Launch of Value-in-Health Regional Issues .Value in Health Regional Issues, , 1 (1 ) ,1 -2

Bian B, Gorevski E, Kelton CML, Guo JJ. Boone JM. (2012. ) Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam. J Managed Care Pharmacy , , 18 (7 ) ,506 -515

Gorevski E, Bian B, Kelton CML, Boone JM, Guo JJ. (2012. ) Drug utilization of benzodiapines in the US Medicaid program from 1991 to 2009. .Ann Pharmacotherapy , , 46 (4 ) ,503 -512

Guo JJ, Kelton CML, Jing Y, Keck PE, Patel N. (2012. ) Potential drug-drug interaction associated with antipsychotic medications in patients with schizophrenia. .Psych Services, , 63 (11 ) ,1080 -1088

Atzinger CB, Guo JJ (2017. ) Biologic disease-modifying antirheumatic drugs in a nation, privately insured population: utilization, expenditures, and price trends. .Am Health Drug Benefit., , 10 (1 ) ,27 -36

Desai V, Kelton CML, Guo JJ, Cavanaugh T, Heaton PC. (2012. ) Drug utilization for antifungal medications in the US Medicaid program from 1991 to 2009. .Clin Ther , , 34 (10 ) ,2118 -2131

Xu X, Rao Y, Abdullah AS, Sharma M, Guo JJ (2017. ) Preventive behaviors in avoiding indoor secondhand smoke exposure among pregnant women in China .BMJ Tobacco Control, , 26 (4 ) ,483 -484

Berry EA, Kelton CM, Guo JJ, Heaton PC. (2013. ) Adaption and application of the Agency for healthcare Research and Quality’s asthma admission rate pediatric quality indicator to Ohio Medicaid claims data. .Res Social Adm Pharma. , , 9 (3 ) ,240 -250.

Almalki ZS, Alahmari AK, Guo JJ, Cavanaugh TM (2016. ) Off-Label Use of Oral Fluoroquinolone Antibiotics in Outpatient Settings in the United States, 2006 to 2012 .Pharmacoepi Drug Safety , , 25 (9 ) ,1042 -1052

Lis Y, Roberts MH, Kamble S, Guo JJ, Raisch DW. (2013. ) Comparison of FDA and EMA Risk Management Implementation for Recent Pharmaceutical Approvals: Report of the International Society for Pharmacoeconomics & Outcomes Research Risk Management Working Group .Value in Health, , 15 (8 ) ,1108 --1118.

Guo JJ*, Chen Y, Du WM, Wigle PR, Papadimitropoulos EA (2016. ) Antithrombotic therapy and direct medical costs in patients with acute coronary syndrome .Value in Health RI , , 9 (c ) ,93 -98

Guo J, Guo JJ (2013. ) Ximelagatran and its risk management plan in the United States. . .Chinese J Pharmacovigilance , , (2 ) ,84-87

Xia Y, Kelton CML, Wigle PR, Heaton P, Guo JJ**. (2016. ) Twenty Yeas of Triptans in the United States Medicaid Programs: utilization and reimbursement trends from 1993 to 2013 .Cephalalgia, , 36 (14 ) ,1305 -1315

Tundia NL, Kelton CML, Cavanaugh TM, Guo JJ, Hanseman DJ, Heaton PC (2013. ) The effect of Electronic-Medical-Record system sophistication on preventive health care for women. .J Am Med Inform Assoc , , 20 (2 ) ,268-76

Gailling B, Roldan A, Nielsen RE, Nielsen J, Gerhard T, Guo JJ, et al. (2016. ) Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: a systematic review and meta-analysis. .JAMA Psychiatry , , 73 (3 ) ,247 -259

Almalki, AZ, Alahmari AK, Guo JJ*, Kelton CML (2012. ) Access to orphan drug in the Middle East: Challenge and Perspective. .Intractable Rare Dis Res , , 1 (4 ) ,139-143

Jones JK, Kingery EE, Tao J, Guo JJ*. (2013. ) Pre-marketing drug safety risk management in the pharmaceutical industry. .Chinese J Pharmacoepidemiology. , , 22 (5 ) ,1 -8

Tie HT, Xi Y, Zeng YS, Zhang Y, Dai CL, Guo JJ, Zhao Y (2013. ) Risk of childhood overweight or obesity associated with excessive weight gain during pregnancy: a meta-analysis. Arch Gynecol Obstet , , 289 (2 ) ,247 -257.

Kelton CML, Guo JJ, Yu Y, Berry EA, Bian B, Heaton PC. (2014. ) Firm- and Drug-Specific Patterns of Generic Drug Payments by U.S. Medicaid Programs: 1991-2008. Applied Health Economics Health Policy, , 12 ,165– -177

Almalki ZS, Guo JJ. (2014. ) Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials .Am Health Drug Benefit, , 7 (6 ) ,318 -328

Xia Y, Kelton CML, Guo JJ, Bian B, Heaton PC. (2015. ) Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010.Obesity, , 23 (8 ) ,1721 -1728

Zhong GC, Wang Y, Zhang Y, Guo JJ (2015. ) Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers.PLOS ONE, , 10 (3 ) ,e0118333.

Guo JJ, Lei J, Xia Y, Yue X (2015. ) Use of health databases for Pharmacoepidemiology and drug safety in therapeutic risk management. .Chinese J Pharmacoepidemiology , , 24 (2 ) ,83- -93

Book Chapter

Guo JJ, Kelton C. (2007 ) Handbook of Pharmaceuticfal Public Policy. Patent protected brand-name drugs and competition between brand-name and generic drugs. [Chapter 20] .(pp. 395 --416). New York, Haworth Press Inc. (Co-Author)

Guo JJ. (2001 ) Traditional Chinese Medicine and Natural Products. Cost-effectiveness and drug safety: critical success factors of Chinese traditional medicine and natural medicine. .(pp. 72 -74).Hong Kong, China, Times Resource Publishing Ltd. (Author)

Guo JJ, Jones JK. (2008 ) Pharmacoepidemiology and Therapeutic Risk Management. Chapter 29: The Story of cisapride and Its Withdraw from Market: A Case Study. (pp. p727- -738).Cincinnati, Ohio, Harvey Whitney Books

Guo JJ, Wade TJ, Pan W, Keller KN. (2011 ) School-Based Health Centers: Cost-Benefit Analysis and Impact on Health Care Disparities. School-Beased Health Care: Advancing Educational Success and Public Health. .(pp. 397- -416).Washington DC., Am Public Health Association Press. (Author)

Guo JJ, Xue S, Mo J (2016 ) Future of Pharmacoepidemiology Chinese Textbook of Pharmacoepidemiology [2nd ed] .(pp. 624 -640).Beijing, China, Chinese Medical Sciences Press (Author)

Guo JJ, Mo J. (2016 ) Use of health database for research in pharmacoepidemiology. Chinese Textbook of Pharmacoepidemiology [2nd ed] .(pp. 97 -114).Beijing, China, Chinese Medical Sciences Press (Author)

Guo JJ, Kelton CML (2015 ) Brand-name drugs and generic drug competitions. Handbook of Pharmaceutical Public Policy (2nd Ed) . (Author)

Guo JJ, Yue XM (2017 ) Cost-containment strategies for drug expenditures in the US and EU health insurances. Chinese Textbook of Pharmaceconomics .(pp. 203 -212).Beijing, China, Chinese Higher Education Press (Author)

Guo JJ (2017 ) Current pharmacoeconomics and research applications Chinese Textbook of Pharmaceconomics .(pp. iv).Beijing, China, Chinese Higher Education Press (Author)

Honors and Awards

2007 -2009 Founder, Chair. ISPOR Asian Consortium Advisory Committee.

2010 Award for the best article published in Pharmacoepidemiology and Drug Safety 2009 “Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter?”

2007 Award for the best Research Article published in J Manag Care Pharm (JMCP) 2006 “Analysis of the effectiveness and cost benefit of leukotriene modifiers in adults with asthma in the Ohio Medicaid population.”

2008 Best poster presentation award at 3rd Asian-Pacific ISPOR conference, Seoul, South Korean "Principal component analysis for drug utilization and expenditure trends"

2010 -2012 President of Soceity for Chinese-American Professors & Scientits (SoCAPS) Cincinnati Chapter

2017 -2018 Council Chair, Society for Chinese American Professors & Scientists (SoCAPS) Type:Recognition

2012 -2018 Co-Editor of Value in Health RI Type:Recognition

Courses Taught

25-PADM-611 STATISTICS FOR PHAR Application of Statistics for Pharmacists Level:Graduate

25-PHDD-705 PHARMVIG & PM SURV Pharmacovigilance and Post-Marketing Surveillance Level:Graduate

25-PADM-571 INTRO PHARM ECON & POLICY Pharmaceutical Economics and Policy Level:Graduate

25-PADM-672 RESPHARMACOEPIDEMOL Research in Pharmacoepidemiology and Drug Safety Level:Graduate

25-PHID-743 RESEARCH PHARM SCI Research Topics in Pharmaceutical Sciences Level:Graduate

25-PHID-971 PHD DISSERTATN RES PhD Dissertation Research Level:Graduate

Graduate Seminar in Pharmaceutical Sciences (Social Administrative Sciences Level:Graduate

Other Information

Post-Doc/Visiting Scholar Advisory Program

  • Bo Yan, MD, MPH. Associate Professor & Associate Dean, College of Pharmacy, Chongqing Medical University. Chongqing, China. June 2016 - Oct 2016. Chair (Dr. Guo). 
  • Feng Chang, PhD.  Associate Professor of pharmaceutical economics, China Pharmaceutical University. Nanjing, Jiangsu. China. Aug 2012 – July 2013. Chair (Dr. Guo).
  •   Wenmin Du, MD, PhD, Chief Patient-Safety Officer, Shanghai State Food Drug Administration (SFDA).        6/2010 – 10/2010        Chair (Dr. Guo)
PhD Student Advising Committees
Xiaomeng Yue (PhD student)     8/2017 - present  Chair (Dr. Guo)
Yihong Deng (PhD student)  8/2014- present  Chair (Dr. Lin)
Abdullah Alahmari (Ph.D. student)      9/2011 – present    Chair (Dr. Guo)
Ziyad Almalki (Ph.D.)                   9/2011 – 5/2017         Chair (Dr. Guo)
Ying Xia (Ph.D.)                           9/2011 – 12/2016         Chair (Dr. Guo)
Christopher Atzinger (Ph.D. student)   3/2010 – present   Chair (Dr. Guo)
Yanjun Zhang (Ph.D. student)      9/2009 – 5/2015         Chair (Dr. Guo)
Boyang Bian (Ph.D. student)        9/2008 – 5/2013         Chair (Dr. Guo)
Nimita Tunida (Ph.D. student)      8/2008 –5/2013          Chair (Dr. Heaton)
Ned Berry (Ph.D. student)            8/2007 – 5/2012         Chair (Dr. Heaton)
Yan Chen (Ph.D.)                         8/2004 –3/2007           Chair (Dr. Guo)
Yonghua Jing (Ph.D. candidate)  8/2004 – 3/2009          Chair (Dr. Guo)
Anthony Louder (Ph.D.)                12/2000 – 12/2005      Chair (Dr. Guo)
Jennie Zimmerman (PhD candidate) 9/2002 – 7/2005;   Chair: (Ray Jang)
Pamela Heaton (Ph.D.)                12/2000 – 8/2003        Chair (Dr. Guo)

MS Student Advising Committees
Xiaomeng Yue (MS)  8/2014 -8/2017  Chair (Dr. Guo)
Jing Guo (MS)         9/2011 – 5/2013         Chair (Dr. Guo)
Jeanine Dahlquist (MS)        9/2009 – 6/2011        Chair-Research Advisor
Gail Geodde-Chin, PharmD (MS)  9/2009 – 6/2011      Chair-Research Advisor
Kari Weddle (MS)      9/2008 – 6/2010                   Chair-Research Advisor
Susan Seddoh (MS)      &,